Tozasertib is a pan-Aurora inhibitor, mostly against Aurora A. Volasertib is an experimental small-molecule inhibitor of the PLK1 (polo-like kinase 1) protein and is developed for use as an anti-cancer agent. This evidence concerns the gene PLK1 and cancer.